NexGel Inc (NXGL) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, NexGel Inc (NASDAQ: NXGL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.88 (-3.72% 1D, market cap $1.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NXGL ranks #906 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NXGL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 39.5%, and ROIC of -35.0%. By comparison, BJDX (Bluejay Diagnostics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and IVF (INVO Fertility Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, NXGL leads on earnings multiple (N/A) while NXGL leads on capital efficiency (-35.0% ROIC).
Per NXGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468929), NexGel Inc generated $11.4M in revenue (+31.5% YoY), -$3.0M in net income, and -$1.4M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While NXGL currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.14) and Max Pain ($4.07) forces dealer call-delta covering toward $56.28.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NexGel Inc (NXGL) dropped -3.72% to $3.88, trading at 2% of its 52-week range ($3 – $53.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
LANGHORNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to p
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive
Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by 14.41% to
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +31.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NXGL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NXGL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, NexGel Inc (NXGL) ranks #906 by composite RQD confidence (32/100, grade E) and #999 by equity capitalization ($1.9M). Within this direct 5-issuer industry benchmark cohort, NXGL leads on earnings valuation at N/A trailing P/E, while NXGL leads on capital efficiency and profitability with -35.0% ROIC and 39.5% gross margin. ICCM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NXGL at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NXGL
ACTIVE
NexGel Inc | E | 32/100 | — | 39.5% | -35.0% | -3.72% | $1.9M | Benchmark Subject |
| BJDX Bluejay Diagnostics Inc. | D | 45/100 | — | — | -35.0% | -5.08% | $2.4M | /bjdx-vs-nxgl → |
| IVF INVO Fertility Inc. | D- | 43/100 | — | 96.0% | -35.0% | -3.60% | $2.5M | /ivf-vs-nxgl → |
| VJET Flyte Aviation Inc. | D | 45/100 | — | 92.3% | -35.0% | +2.94% | $1.4M | /vjet-vs-nxgl → |
| ICCM IceCure Medical Ltd. | D | 46/100 | — | 36.3% | -35.0% | -2.13% | $3.3M | /iccm-vs-nxgl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), NexGel Inc (NXGL) reported GAAP revenue of $11.4M (+31.5% vs. FY2024 revenue of $8.7M , and +179.3% cumulative change since FY2023) , GAAP net income of -$3.0M, operating cash flow of -$1.3M, and free cash flow of -$1.4M (+68.0% YoY). On the balance sheet, NXGL closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.4M | -$3.0M | -$1.3M | -$1.4M | $10.5M | — |
| FY2024 (FY) | 2024-12-31 | $8.7M | -$3.3M | -$3.9M | -$4.3M | $11.0M | — |
| FY2023 (FY) | 2023-12-31 | $4.1M | -$3.2M | -$3.2M | -$3.2M | — | — |
As of 2026-11-01, NexGel Inc (NASDAQ: NXGL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.88 (-3.72% 1D, market cap $1.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NXGL ranks #906 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), NXGL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 39.5%, and ROIC of -35.0%. By comparison, BJDX (Bluejay Diagnostics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and IVF (INVO Fertility Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, NXGL leads on earnings multiple (N/A) while NXGL leads on capital efficiency (-35.0% ROIC).
Per NXGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468929), NexGel Inc generated $11.4M in revenue (+31.5% YoY), -$3.0M in net income, and -$1.4M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NXGL last traded at $3.88 (-3.72% on volume of 14,593 shares), positioning the stock -24.51% below its 50-day simple moving average ($5.14) and -69.03% below its 200-day simple moving average ($12.53). Across its 52-week range of $3.00 to $53.60, NXGL sits at the 1.7% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.40 to $4.36).
Why NXGL Stock dropped -3.72% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).